The EGFR network in bone biology and pathology

Trends in Endocrinology and Metabolism

Volumn 20, Issue 10, 2009, Pages 517-524

  Schneider, Marlon R ^a   Sibilia, Maria ^b   Erben, Reinhold G ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GEFITINIB; PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C RECEPTOR; STRONTIUM RANELATE;

BONE CANCER; BONE DISEASE; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG INTERMITTENT THERAPY; GROWTH PLATE; HORMONE ACTION; HUMAN; KNOCKOUT MOUSE; MESENCHYMAL STEM CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; BONE AND BONES; CHONDROCYTES; HUMANS; OSTEOBLASTS; OSTEOCLASTS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 72149122690     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.06.008     Document Type: Review

References (80)

1. Xian C.J. Roles of epidermal growth factor family in the regulation of postnatal somatic growth. Endocr. Rev. 28 (2007) 284-296
2. Karsenty G., and Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2 (2002) 389-406
3. Schneider M.R., and Wolf E. The epidermal growth factor receptor ligands at a glance. J. Cell. Physiol. 218 (2009) 460-466
4. Oda K., et al. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 1 (2005) 2005
5. Yarden Y., and Shilo B.Z. SnapShot: EGFR signaling pathway. Cell 131 (2007) 1018
6. Nyati M.K., et al. Integration of EGFR inhibitors with radiochemotherapy. Nat. Rev. Cancer 6 (2006) 876-885
7. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2 (2001) 127-137
8. Gschwind A., et al. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4 (2004) 361-370
9. Holbro T., and Hynes N.E. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 195-217
10. Citri A., and Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7 (2006) 505-516
11. Sibilia M., et al. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 75 (2007) 770-787
12. Schneider M.R., et al. Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am. J. Pathol. 173 (2008) 14-24
13. Kronenberg H.M. Developmental regulation of the growth plate. Nature 423 (2003) 332-336
14. Huang L., et al. The role of transforming growth factor alpha in rat craniofacial development and chondrogenesis. J. Anat. 189 (1996) 73-86
15. Yoon Y.M., et al. Epidermal growth factor negatively regulates chondrogenesis of mesenchymal cells by modulating the protein kinase C-alpha, Erk-1, and p38 MAPK signaling pathways. J. Biol. Chem. 275 (2000) 12353-12359
16. Omi M., et al. Studies on epidermal growth factor receptor signaling in vertebrate limb patterning. Dev. Dyn. 233 (2005) 288-300
17. Halevy O., et al. Epidermal growth factor receptor gene expression in avian epiphyseal growth-plate cartilage cells: effect of serum, parathyroid hormone and atrial natriuretic peptide. Mol. Cell. Endocrinol. 75 (1991) 229-235
18. Monsonego E., et al. Growth hormone inhibits differentiation of avian epiphyseal growth-plate chondrocytes. Mol. Cell. Endocrinol. 114 (1995) 35-42
19. Sibilia M., et al. Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. Development 130 (2003) 4515-4525
20. Chan S.Y., and Wong R.W. Expression of epidermal growth factor in transgenic mice causes growth retardation. J. Biol. Chem. 275 (2000) 38693-38698
21. Nakashima K., and de Crombrugghe B. Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet. 19 (2003) 458-466
22. Canalis E., and Raisz L.G. Effect of epidermal growth factor on bone formation in vitro. Endocrinology 104 (1979) 862-869
23. Kumegawa M., et al. Effects of epidermal growth factor on osteoblastic cells in vitro. Calcif. Tissue Int. 35 (1983) 542-548
24. Ng K.W., et al. Stimulation of DNA synthesis by epidermal growth factor in osteoblast-like cells. Calcif. Tissue Int. 35 (1983) 624-628
25. Hata R., et al. Selective inhibition of type I collagen synthesis in osteoblastic cells by epidermal growth factor. Endocrinology 115 (1984) 867-876
26. Fang M.A., et al. The effects of prostaglandin E2, parathyroid hormone, and epidermal growth factor on mitogenesis, signaling, and primary response genes in UMR 106-01 osteoblast-like cells. Endocrinology 131 (1992) 2113-2119
27. Loza J., et al. Role of extracellular calcium influx in EGF-induced osteoblastic cell proliferation. Bone 16 (1995) 341S-347S
28. Chien H.H., et al. Down-regulation of osteoblastic cell differentiation by epidermal growth factor receptor. Calcif. Tissue Int. 67 (2000) 141-150
29. Qin L., et al. Amphiregulin is a novel growth factor involved in normal bone development and in the cellular response to parathyroid hormone stimulation. J. Biol. Chem. 280 (2005) 3974-3981
30. Schneider M.R., et al. High cortical bone mass phenotype in betacellulin transgenic mice is EGFR-dependent. J. Bone Miner. Res. 24 (2009) 455-467
31. Jhappan C., et al. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61 (1990) 1137-1146
32. Sandgren E.P., et al. Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61 (1990) 1121-1135
33. Provenzano A.P., et al. Heparin-binding EGF-like growth factor (HB-EGF) overexpression in transgenic mice downregulates insulin-like growth factor binding protein (IGFBP)-3 and -4 mRNA. Growth Factors 23 (2005) 19-31
34. Poole K.E., and Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Curr. Opin. Pharmacol. 5 (2005) 612-617
35. Partridge N.C., et al. Understanding parathyroid hormone action. Ann. N. Y. Acad. Sci. 1068 (2006) 187-193
36. Drake M.T., et al. Parathyroid hormone increases the expression of receptors for epidermal growth factor in UMR 106-01 cells. Endocrinology 134 (1994) 1733-1737
37. Gonzalez E.A., and Martin K.J. Retinoids modulate the effect of PTH and calcitriol on EGF receptor expression in UMR 106-01 cells. Calcif. Tissue Int. 58 (1996) 429-434
38. Gonzalez E.A., et al. Mechanisms of the regulation of EGF receptor gene expression by calcitriol and parathyroid hormone in UMR 106-01 cells. Kidney Int. 61 (2002) 1627-1634
39. Ahmed I., et al. Transactivation of the epidermal growth factor receptor mediates parathyroid hormone and prostaglandin F2 alpha-stimulated mitogen-activated protein kinase activation in cultured transgenic murine osteoblasts. Mol. Endocrinol. 17 (2003) 1607-1621
40. Qin L., et al. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J. Biol. Chem. 278 (2003) 19723-19731
41. Satomura K., et al. Receptor tyrosine kinase expression in human bone marrow stromal cells. J. Cell. Physiol. 177 (1998) 426-438
42. Krampera M., et al. HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells, inducing cell expansion and reversibly preventing multilineage differentiation. Blood 106 (2005) 59-66
43. Normanno N., et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr. Relat. Cancer 12 (2005) 471-482
44. Deans R.J., and Moseley A.B. Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 28 (2000) 875-884
45. Arthur A., et al. The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J. Cell. Physiol. 218 (2009) 237-245
46. Kuznetsov S.A., et al. Factors required for bone marrow stromal fibroblast colony formation in vitro. Br. J. Haematol. 97 (1997) 561-570
47. Tamama K., et al. Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells 24 (2006) 686-695
48. Liu Y., et al. Wound repair by bone marrow stromal cells through growth factor production. J. Surg. Res. 136 (2006) 336-341
49. Boyle W.J., et al. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
50. Teitelbaum S.L., and Ross F.P. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4 (2003) 638-649
51. Raisz L.G., et al. Direct stimulation of bone resorption by epidermal growth factor. Endocrinology 107 (1980) 270-273
52. Stern P.H., et al. Human transforming growth factor-alpha stimulates bone resorption in vitro. J. Clin. Invest 76 (1985) 2016-2019
53. Ibbotson K.J., et al. Human recombinant transforming growth factor alpha stimulates bone resorption and inhibits formation in vitro. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 2228-2232
54. Lorenzo J.A., et al. Effects of DNA and prostaglandin synthesis inhibitors on the stimulation of bone resorption by epidermal growth factor in fetal rat long-bone cultures. J. Clin. Invest. 77 (1986) 1897-1902
55. Takahashi N., et al. Recombinant human transforming growth factor-alpha stimulates the formation of osteoclast-like cells in long-term human marrow cultures. J. Clin. Invest. 78 (1986) 894-898
56. Tashjian Jr. A.H., et al. Actions of growth factors on plasma calcium. Epidermal growth factor and human transforming growth factor-alpha cause elevation of plasma calcium in mice. J. Clin. Invest. 78 (1986) 1405-1409
57. Marie P.J., et al. Effects of epidermal growth factor on bone formation and resorption in vivo. Am. J. Physiol. 258 (1990) E275-E281
58. Wang K., et al. Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J. Biol. Chem. 279 (2004) 53848-53856
59. Zhu J., et al. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts, implications for osteolytic bone metastases. J. Biol. Chem. 282 (2007) 26656-26664
60. Anandarajah A.P. Role of RANKL in bone diseases. Trends Endocrinol. Metab. 20 (2009) 88-94
61. Kim M.S., et al. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase. NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption. J. Biol. Chem. 281 (2006) 1274-1285
62. Yi T., et al. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling. J. Cell. Physiol. 217 (2008) 409-422
63. van der Zee E., et al. EGF and IL-1 alpha modulate the release of collagenase, gelatinase and TIMP-1 as well as the release of calcium by rabbit calvarial bone explants. J. Periodontal Res. 33 (1998) 65-72
64. Yakar S., and Rosen C.J. From mouse to man, redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp. Biol. Med. (Maywood) 228 (2003) 245-252
65. Bonassar L.J., and Trippel S.B. Interaction of epidermal growth factor and insulin-like growth factor-I in the regulation of growth plate chondrocytes. Exp. Cell Res. 234 (1997) 1-6
66. Hallak H., et al. Epidermal growth factor-induced activation of the insulin-like growth factor I receptor in rat hepatocytes. Hepatology 36 (2002) 1509-1518
67. Takaoka M., et al. EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. Am. J. Physiol. Gastrointest. Liver Physiol. 290 (2006) G404-G416
68. Wen Y.H., et al. Epidermal growth factor receptor in osteosarcoma, expression and mutational analysis. Hum. Pathol. 38 (2007) 1184-1191
69. Dobashi Y., et al. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors. Hum. Pathol. 38 (2007) 914-925
70. Vered M., et al. Epidermal growth factor receptor expression in ameloblastoma. Oral Oncol. 39 (2003) 138-143
71. Di Lorenzo G., et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 8 (2002) 3438-3444
72. Choueiri M.B., et al. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev. 25 (2006) 601-609
73. Buijs J.T., and van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Lett. 273 (2009) 177-193
74. Soulitzis N., et al. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int. J. Oncol. 29 (2006) 305-314
75. Angelucci A., et al. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr. Relat. Cancer 13 (2006) 197-210
76. Kim S.J., et al. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res. 64 (2004) 4201-4208
77. Weber K.L., et al. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res. 63 (2003) 2940-2947
78. Roodman G.D. Biology of osteoclast activation in cancer. J. Clin. Oncol. 19 (2001) 3562-3571
79. Miettinen P.J., et al. Epidermal growth factor receptor function is necessary for normal craniofacial development and palate closure. Nat. Genet. 22 (1999) 69-73
80. Schneider M.R., et al. Betacellulin overexpression in transgenic mice causes disproportionate growth, pulmonary hemorrhage syndrome, and complex eye pathology. Endocrinology 146 (2005) 5237-5246